(Q36704499)

15 August 2017

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease (English)

1 reference

15 August 2017

2

Rosario Pivonello

1 reference

15 August 2017

Maria Fleseriu

1

1 reference

15 August 2017

Jacques Young

3

1 reference

15 August 2017

Amir H Hamrahian

4

1 reference

15 August 2017

Mark E Molitch

5

1 reference

15 August 2017

Chikara Shimizu

6

1 reference

15 August 2017

Tomoaki Tanaka

7

1 reference

15 August 2017

Akira Shimatsu

8

1 reference

15 August 2017

Tracy White

9

1 reference

15 August 2017

Annie Hilliard

10

1 reference

15 August 2017

Chuan Tian

11

1 reference

15 August 2017

Nicholas Sauter

12

1 reference

15 August 2017

Beverly M K Biller

13

1 reference

15 August 2017

Xavier Bertagna

14

1 reference

15 August 2017

5 November 2015

1 reference

15 August 2017

1 reference

15 August 2017

19

1 reference

15 August 2017

2

1 reference

15 August 2017

138-148

1 reference

Creative Commons Attribution 4.0 International

15 August 2017

start time

5 November 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s11102-015-0692-z

0 references

cites work

The Treatment of Cushing's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Treatment of Cushing's disease: a mechanistic update

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Molecular basis of pharmacological therapy in Cushing's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Efficacy of medical treatment in Cushing's disease: a systematic review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Medical management of Cushing's disease: what is the future?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Management of Cushing disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing's disease: care reality in the Munich Metropolitan Region.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799251

Testosterone and cardiovascular disease

5 September 2018

1 reference

PubMed

12 December 2020

Ketoconazole in Cushing's disease: is it worth a try?

1 reference

PubMed

12 December 2020

Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

10.1007/S11102-015-0692-Z

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

1 reference